Browse the search results

For the first time, the spectrum of genes and pathways interacting with alternative DNA structures called G-quadruplexes in humans is revealed highlighting new possibilities for the pursuit of cancer therapies.

RUNX2 plays an important role in human NK cell biology by driving differentiation, inhibiting cytokine production, and inducing a tissue-resident phenotype, which has implications for improving NK cell therapy for cancer patients.

Novel human models of the lung and intestine are described and validated as preclinical in vitro tools for predictive profiling of T-cell-bispecific antibodies with expected on-target off-tumor risk.

A novel method predicts cancer and immune cell types from bulk tumor gene expression data with the ability to consider uncharacterized and possibly highly variable cell types, which is validated in human genome.

Skin epithelium can tolerate oncogene-expressing clones through a novel cellular mechanism of inter-clonal competition between renewing progenitors along the clone's edge and differentiating progenitors within the clone's core.

Data-driven systems biology models of signaling predict cellular response to untested perturbations and can nominate drug combinations to overcome drug resistance in cancer cells.

Tailoring Boolean models to 488 prostate cancer patients and 8 cell lines data allows for the experimentally validated personalisation of drug treatments.

A project to repeat experiments from high-impact papers in cancer biology did not complete all replications, with challenges ranging from mundane reasons to unexpected methodological issues.